These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8072117)
1. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. Kotoh S; Naito S; Sakamoto N; Goto K; Kumazawa J J Urol; 1994 Oct; 152(4):1267-70. PubMed ID: 8072117 [TBL] [Abstract][Full Text] [Related]
2. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Naito S; Sakamoto N; Kotoh S; Goto K; Matsumoto T; Kumazawa J Eur Urol; 1992; 22(2):158-62. PubMed ID: 1362155 [TBL] [Abstract][Full Text] [Related]
3. Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein. Kondo Y; Yamagata K; Satoh M; Himeno S; Imura N; Nishimura T J Urol; 2003 Dec; 170(6 Pt 1):2467-70. PubMed ID: 14634452 [TBL] [Abstract][Full Text] [Related]
4. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522 [TBL] [Abstract][Full Text] [Related]
5. Metallothionein gene expression in bladder cancer exposed to cisplatin. Wood DP; Klein E; Fair WR; Chaganti RS Mod Pathol; 1993 Jan; 6(1):33-5. PubMed ID: 8426855 [TBL] [Abstract][Full Text] [Related]
6. The correlation of membranous glycoprotein-gp-170, cytoplasmic glutathione and glucose-6-phosphate dehydrogenase levels with multidrug resistance in transitional cell carcinoma cell lines of the urinary tract. Yu DS; Chang SY; Ma CP J Urol; 1997 Feb; 157(2):727-31. PubMed ID: 8996407 [TBL] [Abstract][Full Text] [Related]
7. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. Wülfing C; van Ahlen H; Eltze E; Piechota H; Hertle L; Schmid KW World J Urol; 2007 Apr; 25(2):199-205. PubMed ID: 17253087 [TBL] [Abstract][Full Text] [Related]
8. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Bilim V; Kasahara T; Hara N; Takahashi K; Tomita Y Int J Cancer; 2003 Jan; 103(1):29-37. PubMed ID: 12455050 [TBL] [Abstract][Full Text] [Related]
9. Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines. Koga H; Kotoh S; Nakashima M; Yokomizo A; Tanaka M; Naito S Int J Oncol; 2000 May; 16(5):1003-7. PubMed ID: 10762637 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Hayashi H; Kuwahara M; Fujisaki N; Furihata M; Ohtsuki Y; Kagawa S Oncol Rep; 2001; 8(6):1275-9. PubMed ID: 11605048 [TBL] [Abstract][Full Text] [Related]
11. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. Yamasaki Y; Smith C; Weisz D; van Huizen I; Xuan J; Moussa M; Stitt L; Hideki S; Cherian MG; Izawa JI Urology; 2006 Mar; 67(3):530-5. PubMed ID: 16504266 [TBL] [Abstract][Full Text] [Related]
13. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Koropatnick J; Pearson J Mol Pharmacol; 1993 Jul; 44(1):44-50. PubMed ID: 8341278 [TBL] [Abstract][Full Text] [Related]
14. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510 [TBL] [Abstract][Full Text] [Related]
15. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211 [TBL] [Abstract][Full Text] [Related]
16. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991 [TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin]. Ribrag V; Ghnassia M; Théodore C; Ghosn M; Piot G; Beurton D; Cukier J; Droz JP J Urol (Paris); 1990; 96(7):373-4. PubMed ID: 2290037 [TBL] [Abstract][Full Text] [Related]
18. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract. Lee SE; Hong SK; Han BK; Yu JH; Han JH; Jeong SJ; Byun SS; Park YH; Choe G Jpn J Clin Oncol; 2007 Jan; 37(1):49-55. PubMed ID: 17204506 [TBL] [Abstract][Full Text] [Related]